Currently, U.S. FDA-approved PDE inhibitors are used for treating heart failure and pulmonary hypertension and for treating peripheral artery disease and prophylaxis after surgery for thromboembolism (Sheng et al., 2022[95]). The gene discussed is ALDH7A1; the disease is pulmonary arterial hypertension.